These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8643208)

  • 1. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure.
    Zucchelli P; Zuccalà A; Gaggi R
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():46-51. PubMed ID: 8643208
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium channel blockers: effects on progressive renal disease.
    Zucchelli P; Zuccalà A; Gaggi R
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):94-7. PubMed ID: 2024684
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure.
    Amann K; Törnig J; Nichols C; Zeier M; Mall G; Ritz E
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():33-8. PubMed ID: 8643206
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium antagonists and renal protection: emerging perspectives.
    Epstein M
    J Hypertens Suppl; 1998 Sep; 16(4):S17-25. PubMed ID: 9817188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.
    Remuzzi G
    Int J Clin Pract Suppl; 2000 May; (110):9-15. PubMed ID: 10912302
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sympathetic overactivity in hypertensive patients with chronic renal disease.
    Remuzzi G
    N Engl J Med; 1999 Apr; 340(17):1360-1. PubMed ID: 10219074
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcium antagonists and renal failure progression.
    Robles NR
    Ren Fail; 2008; 30(3):247-55. PubMed ID: 18350443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure and progression of renal failure in the elderly.
    Acone D; Cante D; Cillo F; Giordano G; Giordano C
    Kidney Int Suppl; 1996 Jun; 55():S75-7. PubMed ID: 8743516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of felodipine in patients with refractory hypertension and progressive renal disease.
    Herlitz H; Nyberg G; Granérus G; Björck S; Aurell M
    Scand J Urol Nephrol Suppl; 1988; 108():31-4. PubMed ID: 3163828
    [No Abstract]   [Full Text] [Related]  

  • 15. Lercanidipine in patients with chronic renal failure: the ZAFRA study.
    Robles NR; Ocon J; Gomez CF; Manjon M; Pastor L; Herrera J; Villatoro J; Calls J; Torrijos J; Rodríguez VI; Rodriguez MM; Mendez ML; Morey A; Martinez FI; Marco J; Liebana A; Rincon B; Tornero F
    Ren Fail; 2005; 27(1):73-80. PubMed ID: 15717638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypertension in chronic renal insufficiency.
    Locatelli F; Manzoni C; Marcelli D
    J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 20. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.